Merck oral PCSK9 inhibitor macrocycle chemical structure drug hunter molecules of the year

macrocyclic PCSK9/LDLR PPI inhibitor

oral PD in Ph. I with MK-0616

from mRNA display screen and SBDD

published example: compound 44

Merck & Co.

MK-0616 is a macrocyclic PCSK9 inhibitor with demonstrated once-daily PCSK9-lowering and LDL-cholesterol-lowering activities in a human clinical trial (<300 mg QD). Currently PCSK9-targeting therapies are only available by injection,…


     this content is exclusive to
    Premium members

    Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.